{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:33:24Z","timestamp":1760232804840,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccinations have helped to control the COVID-19 pandemic; however, few studies focus on the adverse effects and allergic reactions of these vaccines and fewer have a scope in the Latin American population. The objective of this study was to assess the associations between vaccinations, sex, age, allergic reactions, and adverse effects. This was an analytical cross-sectional study conducted between 1 July and 1 October 2022. The sample consisted of 443 surveyed participants, with a total of 1272 COVID-19 vaccine doses. Seven vaccines (Pfizer BioNTech, Oxford-AstraZeneca, CanSino, Moderna, Johnson and Johnson, Sinovac, and Sputnik V) were evaluated. A total of 12.6% of those surveyed had at least one allergic reaction posterior to vaccination, and females had a greater chance of developing one (p &lt; 0.001, OR 3.1). The most common allergic reaction was chest pain, and Pfizer-BioNTech and Oxford-AstraZeneca were associated with the onset of allergic reactions (p &lt; 0.005). A total of 54.6% of those surveyed developed adverse effects, the most common of which were myalgia, fever, cephalea, asthenia or adynamia, and arthralgia; moreover, older age was associated with the onset of adverse effects (p &lt; 0.5). This study concludes that the BNT162b2 (Pfizer BioNTech) and ChAdOX1 nCOV-19 (Oxford-AstraZeneca) vaccines are strongly associated with the onset of allergic reactions, with ORs of 1.6 (CI 95%, 1.18 to 2.3) and 1.87 (CI 95%, 1.35 to 2.6), respectively. In addition, females have a greater chance of developing allergic reactions associated with COVID-19 vaccinations, and there was a relation found between older age and a greater prevalence of comorbidities, adverse effects after vaccination, and COVID-19 infection after vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10122012","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T04:01:33Z","timestamp":1669608093000},"page":"2012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-6824","authenticated-orcid":false,"given":"Jes\u00fas Maximiliano","family":"Granados Villalpando","sequence":"first","affiliation":[{"name":"Cardiometabolism Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio de Jesus","family":"Romero Tapia","sequence":"additional","affiliation":[{"name":"Health Sciences Academic Division (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe del Carmen","family":"Baeza Flores","sequence":"additional","affiliation":[{"name":"Cardiometabolism Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luis","family":"Ble Castillo","sequence":"additional","affiliation":[{"name":"Metabolic Disease Biochemistry Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isela Esther","family":"Juarez Rojop","sequence":"additional","affiliation":[{"name":"Lipid Metabolism Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frida Isabel","family":"Lopez Junco","sequence":"additional","affiliation":[{"name":"Cardiometabolism Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viridiana","family":"Olvera Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Metabolic Disease Biochemistry Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-8283","authenticated-orcid":false,"given":"Sergio","family":"Quiroz Gomez","sequence":"additional","affiliation":[{"name":"Health Sciences Academic Division (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-333X","authenticated-orcid":false,"given":"Jes\u00fas Arturo","family":"Ruiz Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Research Center for Tropical and Emerging Diseases, High Specialty Regional Hospital \u201cDr. Juan Graham Casas\u00fas\u201d, Villahermosa 86126, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-1314","authenticated-orcid":false,"given":"Crystell Guadalupe","family":"Guzm\u00e1n Priego","sequence":"additional","affiliation":[{"name":"Cardiometabolism Laboratory, Research Center, Academic Division of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa 86040, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020). Naming the Coronavirus Disease (COVID-19) and the Virus that Causes It, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1111\/jcmm.15364","article-title":"Scientific research progress of COVID-19\/SARS-CoV-2 in the first five months","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2021). COVID-19: Characteristics and Therapeutics. Cells, 10.","DOI":"10.3390\/cells10020206"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing COVID-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/jmv.27810","article-title":"Vaccines for COVID-19: An insight on their effectiveness and adverse effects","volume":"94","author":"Qamar","year":"2022","journal-title":"J. Med. Vir."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"COVID-19 Vaccines\u2014Immunity, Variants, Boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.idc.2022.01.008","article-title":"COVID-19 Vaccines","volume":"36","author":"Hahn","year":"2022","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: The first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jop.13165","article-title":"Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns","volume":"50","author":"Cirillo","year":"2021","journal-title":"J. Oral Pathol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1002\/jmv.27214","article-title":"Safety of COVID-19 vaccines","volume":"93","author":"Alkhaffaf","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and Joint Council of Allergy, Asthma and Immunology (2010). Drug allergy: An updated practice parameter. Ann. Allergy Asthma Immunol., 105, 259\u2013273.","DOI":"10.1016\/j.anai.2010.08.002"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7774\/cevr.2014.3.1.50","article-title":"Vaccine allergies","volume":"3","year":"2014","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.det.2021.05.016","article-title":"COVID-19 vaccines and the skin. The landscape of cutaneous vaccine reactions worldwide","volume":"39","author":"Sun","year":"2021","journal-title":"Dermatol. Clin."},{"key":"ref_16","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristic and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, P.-Y., Wu, B.-J., Su, M.-C., Lin, Y.-H., Chiang, S.-C., Wu, J.-C., Chen, T.-J., and Chen, Y.-C. (2022). RiskFactors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose. Vaccines, 10.","DOI":"10.3390\/vaccines10071115"},{"key":"ref_19","first-page":"1","article-title":"Sec. Family Medicine and Primary Care","volume":"10","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_20","first-page":"1453","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2017","journal-title":"Lancet"},{"key":"ref_21","unstructured":"Secretar\u00eda de Salud (2022, October 17). Estrategia Nacional de Vacunaci\u00f3n.2022. COVID-19 Comunicado T\u00e9cnico. 04 de Julio de 2022. Available online: https:\/\/www.gob.mx\/salud\/documentos\/informe-tecnico-diario-covid19-2022."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.2147\/IJGM.S376316","article-title":"The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study","volume":"15","author":"Bagher","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3855\/jidc.15545","article-title":"Side effects of the Pfizer BioNTech vaccine in health workers of a hospital in the southeast of Mexico","volume":"16","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_25","first-page":"e23526","article-title":"Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review","volume":"14","author":"Dighriri","year":"2022","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imj.15623","article-title":"Pfizer\/BioNtech BNT162b2: Adverse events and insights from an Australian mass vaccination clinic for COVID-19","volume":"52","author":"Halder","year":"2022","journal-title":"Intern. Med. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_28","first-page":"e2021069","article-title":"ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: A cross-sectional study from Western Nepal","volume":"5","author":"Paudel","year":"2021","journal-title":"J. Glob. Health Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"760047","DOI":"10.3389\/fmed.2021.760047","article-title":"BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees","volume":"8","author":"Alghamdi","year":"2021","journal-title":"Front. Med."},{"key":"ref_30","first-page":"2678","article-title":"COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study","volume":"20","author":"Attash","year":"2022","journal-title":"Pharm. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Green, M.S., Peer, V., Magid, A., Hagani, N., Anis, E., and Nitzan, D. (2022). Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines, 10.","DOI":"10.3390\/vaccines10020233"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fmed.2021.700014","article-title":"Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management","volume":"8","author":"Xiong","year":"2021","journal-title":"Front. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea","volume":"36","author":"Bae","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Mekhemar, M., Conrad, J., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., Klugar, M., and Attia, S. (2021). Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. Vaccines, 9.","DOI":"10.3390\/vaccines9060673"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.3389\/fpubh.2022.937794","article-title":"Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study","volume":"10","author":"Yesuf","year":"2022","journal-title":"Front. Public Health"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:26:42Z","timestamp":1760146002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122012"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122012","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,11,25]]}}}